Ellipses Pharma

Ellipses Pharma is a private, UK-based biotech with a unique drug development model designed to de-risk and accelerate oncology therapeutics. Its strategy involves unbiased search and evaluation to in-license clinical-stage assets, followed by streamlined development with uninterrupted funding. The company has built a pipeline through partnerships, including a first-in-class B7H3 ADC from Innolake and a next-generation RET inhibitor (EP0031/A400) with Kelun Biotech, which has an NDA under review in China. Led by veteran biotech entrepreneur Professor Sir Christopher Evans, Ellipses aims to rapidly bring new cancer treatments to patients.

An operational and financial model focused on unbiased search & evaluation, in-licensing of clinical-stage oncology assets, and development with uninterrupted funding to accelerate drug development.

Ellipses competes with a vast array of oncology-focused biotechs and large pharma companies. Its differentiation lies in its capital-efficient, asset-centric model rather than a proprietary technology, competing on speed and deal-making acumen to advance programs that others may have deprioritized.